Dual T cell receptor/chimeric antigen receptor engineered NK‐92 cells targeting the HPV16 E6 oncoprotein and the tumor‐associated antigen L1CAM exhibit enhanced cytotoxicity and specificity against tumor cells
Article in Journal of Medical Virology (April 2024)